Abstract: Arc flash mitigation devices are employed to protect personnel during maintenance of photovoltaic inverters. During normal operation, an alternating current (AC) output of a photovoltaic inverter is coupled to a low voltage winding of a step up transformer through a bus-bar (e.g., an electrically conductive interconnect), which has higher current rating than a fuse. During maintenance, the bus-bar is replaced with the fuse. The fuse may be employed in conjunction with a switch. The switch may be a disconnect switch that places the bus-bar in parallel with the fuse during normal operation, and decouples the bus-bar from the fuse during maintenance. The switch may also be a transfer switch that places either the bus-bar or the fuse in series with the AC output of the photovoltaic inverter and the low voltage winding of the step up transformer.

Abstract: The present invention, relates to solid state forms of N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide represented by the following structural formula-1 and process for their preparation. The present invention also relates to an improved process for the preparation of N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide compound of formula-1 and intermediates thereof.

Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

Abstract: Disclosed herein are system, method, and computer program product embodiments for extending data models and processes in a cloud platform. An embodiment operates by selecting an entity metadata in the cloud platform. The embodiment defines an extension metadata for the entity metadata. The embodiment defines an extended entity metadata based on the entity metadata and the extension metadata. The embodiment then creates an extended entity instance in the cloud platform based on the extended entity metadata.

Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.

Abstract: Compounds of formula (I) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:

Abstract: The present invention is relates to an improved process for the preparation (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabi-cyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone of formula I.

Abstract: This invention pertains to the use of fused bicycle heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.

Abstract: The present invention relates to process for the preparation of (2S)—N—((S)-1-((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenyethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4- methylpentanamide represented by the following structural formula-1.

Abstract: The present invention relates to a novel and improved process for the preparation of Sitagliptin of Formula (I) and its pharmaceutically acceptable salts. The present invention also relates to novel intermediates and process for the preparation of intermediates used in the preparation of Sitagliptin.

Abstract: An apparatus and method of manufacturing the apparatus is provided. The apparatus comprises a first transducer (107) and a first tank. The first transducer (107) is adapted to transmit ultrasonic waves of a first wavelength into the first tank (101). The first tank (101) is configured to establish a substantially standing ultrasonic wave pattern of the ultrasonic waves inside the first tank (101). A disposer (109.1, 109.2) adapted to dispose a textile (131) into the first tank (101) is provided. The disposer (109.1, 109.2) disposes the textile (131) into the first tank at a first distance from the first transducer (107). The first distance is determined based the first wavelength.

Abstract: The invention pertains to the use of compounds represented by the formula, Q-G1-G2-G3-G4-Z, where Q is The compounds can be used as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also can be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.

Abstract: The invention provides systems and methods for managing mobile devices of supported by different platforms. In some embodiments, the invention provides this management capability by utilizing one or more agents or modules native to the platforms themselves to provide interaction with individual mobile. In some embodiments, the invention provides an abstraction layer by which management tasks or other functions relating to mobile devices of different types may be generally defined and translated for application to mobile devices supported by different platforms. In some embodiments, the invention utilizes existing organizational structure of an enterprise or organization to define management permission for mobile device administrators and end users as well as to define policy configuration schemes for mobile devices. In some embodiments, the invention tracks the lifecycle of mobile devices within an enterprise or organization as assets within the organization.

Abstract: Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.

Abstract: Benzimidazole, benzopyrazole and benzotriazole compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.

Abstract: Compounds of formula (I) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:

Abstract: Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (I): and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of CCR2 receptors.

Abstract: Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or Co-crystals and prodrugs thereof.

Abstract: Compounds of formula (I) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6: